Raltegravir (Isentress®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015001227
English
Authors' recommendations:
Raltegravir (Isentress®) 100 mg granules for oral suspension, in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, children, toddlers and infants from the age of four weeks are recommended as an option for restricted use within NHS Wales. Raltegravir (Isentress®) 100 mg granules for oral suspension should be restricted for use in patients who are resistant or intolerant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs), or for whom these options are compromised due to drug–drug interactions.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2366
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Drug Interactions
- HIV Infections
- Protease Inhibitors
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.